VanEck Associates’s Cytokinetics CYTK Stock Holding History

VanEck Associates’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-54,364	Closed	-$2.56M	–	1394
2024 Q4	$2.56M	Sell	54,364 -17,327	-24%	-$900K	﹤0.01%	909
2024 Q3	$3.8M	Buy	71,691 +12,565	+21%	+$700K	﹤0.01%	744
2024 Q2	$3.2M	Buy	59,126 +1,233	+2%	+$74.4K	﹤0.01%	737
2024 Q1	$4.06M	Buy	+57,893	New	+$4.48M	0.01%	661

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VanEck Associates's CYTK Position: Q1 2025 in Review

VanEck Associates sold out of Cytokinetics (CYTK) in Q1 2025, closing a stake of 54,364 shares — an estimated $2.56M sold.

VanEck Associates first reported a position in CYTK in Q1 2024 and held it in 4 quarters. The position peaked at $4.06M in Q1 2024. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.

VanEck Associates reported no remaining Cytokinetics position as of Q1 2025 after selling out during the quarter.
VanEck Associates sold 54,364 Cytokinetics shares in Q1 2025, an estimated $2.56M.
VanEck Associates first reported a position in Cytokinetics in Q1 2024 and held it in 4 quarters.
VanEck Associates's Cytokinetics position peaked at $4.06M in Q1 2024.
355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.

Based on VanEck Associates's 13F filing for Q1 2025, filed 15 May 2025.